Penumbra, Inc. (PEN)
After hours:
| Previous Close | 210.00 |
| Open | 205.91 |
| Bid | 191.00 x 800 |
| Ask | 244.89 x 800 |
| Day's Range | 199.54 - 220.41 |
| 52 Week Range | 180.93 - 348.67 |
| Volume | |
| Avg. Volume | 368,077 |
| Market Cap | 7.871B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 87.92 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Penumbra, Inc. Reports First Quarter 2024 Financial Results
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024.
- PR Newswire
Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024.
- PR Newswire
Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots
Penumbra, Inc. (NYSE: PEN), the world's largest thrombectomy company, announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash™ 2.0, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary emboli (PE). Lightning Flash 2.0 features advanced Lightning Flash algorithms, designed for increased speed and sensitivity to thrombus and blood flow. These new advancements combined with Penumbra's novel cathet
